BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC) - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2017

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Dates et versions

hal-02383647 , version 1 (27-11-2019)

Identifiants

Citer

Audrey Benyamine, Céline Loncle, Etienne D Foucher, Juan-Luis Blazquez, Céline Castanier, et al.. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). OncoImmunology, 2017, 7 (1), pp.e1372080. ⟨10.1080/2162402X.2017.1372080⟩. ⟨hal-02383647⟩
99 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More